Publications
2019
. EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer. European Society of Medical Oncology (ESMO) 2019 Congress. (Abstract ID 503P).
Read More > European Society of Medical Oncology 2019 Congress Poster. Next generation N-terminal domain androgen receptor inhibitor with improved potency and metabolic stability in castration-resistant poster cancers models. Genitourinary Cancers Symposium 2019. (Abstract# MP34-04).
Read More > American Urological Association Poster. Next generation N-terminal domain androgen receptor inhibitor with improved potency and metabolic stability in castration-resistant poster cancers models. Genitourinary Cancers Symposium 2016. (Abstract# 220).
Read More > American Association for Cancer Research Poster. Next generation N-terminal domain androgen receptor inhibitor with improved potency and metabolic stability in castration-resistant poster cancers models. Genitourinary Cancers Symposium 2019. (Abstract# 220).
Read More > Genitouronary Cancers Symposium Poster. Lessons Learned from the metastatic castration-resistant phase 1 of EPI-506, a first-generation androgen receptor N-terminal domain inhibitor. Genitourinary Cancers Symposium 2019. (Abstract# 257).
Read More > Genitouronary Cancers Symposium Poster